Literature DB >> 24762491

Surgery in cerebral metastases: are numbers so important?

Alessandro Agnoletti, Camilla Mencarani, Pier Paolo Panciani1, Lucio Buffoni, Gabriele Ronchetti, Giannantonio Spena, Fulvio Tartara, Michela Buglione, Manuela Pagano, Alessandro Ducati, Marco Fontanella, Diego Garbossa.   

Abstract

BACKGROUND: The prognosis of cerebral metastases (MTS) is linked to progression of both systemic and local disease. The importance of MTS resection has been already pointed out. The observation of a high mortality for not-neurological causes confirms that the modern treatments allow a significant control of the disease within the nervous system. Nevertheless, management difficulties increase with multiple lesions and in these cases the role of surgery has still to be defined.
MATERIALS AND METHODS: We collected the clinical data of patients operated in two centers for cerebral MTS from lung carcinoma during 8 years. Patient selection for surgery followed definite criteria; the limit for multiple MTS was three. We analyzed the functional and survival outcomes of the cohort. RESULTS AND
CONCLUSIONS: Our series included 242 patients: 105 had multiple MTS. Statistical analysis did not show significant differences in mean survival and outcomes between patients with single and multiple lesions. The decease occurred for neurological causes in 15.7% of cases. The selection of candidates for surgery requires several considerations and entails the success rate of this treatment. In patients with the multiple lesions who fulfilled the selection criteria we observed a nevertheless satisfying success after the operation. Our results imply that surgery may be applied also in selected patients with more diffuse intracranial disease. A pre-operative accurate patient selection is related to acceptable quality-of-life following the operation even in cases of multiple MTS.

Entities:  

Mesh:

Year:  2014        PMID: 24762491     DOI: 10.4103/0973-1482.131390

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  2 in total

1.  The treatment of patients with 1-3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis.

Authors:  Michela Buglione; Sara Pedretti; Stefano Gipponi; Luciano Buttolo; Paolo Panciani; Pietro Luigi Poliani; Roberto Liserre; Paolo Borghetti; Ludovica Pegurri; Loredana Costa; Luca Triggiani; Nadia Pasinetti; Paolo Ghirardelli; Sara Pandini; Alessandro Padovani; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2015-04-28       Impact factor: 3.469

2.  Whole brain radiotherapy with adjuvant or concomitant boost in brain metastasis: dosimetric comparison between helical and volumetric IMRT technique.

Authors:  Paolo Borghetti; Sara Pedretti; Luigi Spiazzi; Rossella Avitabile; Mauro Urpis; Federica Foscarini; Giulia Tesini; Francesca Trevisan; Paolo Ghirardelli; Sara Angela Pandini; Luca Triggiani; Stefano Maria Magrini; Michela Buglione
Journal:  Radiat Oncol       Date:  2016-04-19       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.